Clinical considerations of CDK4/6 inhibitors in triple-negative breast cancer
Runtian Wang1, Kun Xu1, Fangyan Gao1
1Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Abstract:
The formation of cyclinD-CDK4/6 complex plays vital roles in the cell cycle transition from G1 phase to S phase which is characterized by vigorous transcription and synthesis. Through cyclinD-CDK4/6-Rb axis, CDK4/6 inhibitors arrest the cell cycle in the G1 phase and block the proliferation of aggressive cells, exhibiting promising effects in containing the aggressiveness of breast cancers. To date, there are three CDK4/6 inhibitors approved by the U.S. Food and Drug Administration in treating advanced hormone receptor-positive breast cancer, including palbociclib, abemaciclib, and ribociclib. In fact, several preclinical experiments and clinical trials presented therapeutic effects of CDK4/6 inhibitor-based treatment in triple-negative breast cancer.
Insights
CDK4/6 inhibitors, like palbociclib, block cancer cell proliferation by halting the cell cycle. These inhibitors show promise in treating advanced hormone receptor-positive breast cancer and are being explored for triple-negative breast cancer.
Area of Science:
- Oncology
- Cell Biology
- Pharmacology
Background:
- The cyclinD-CDK4/6 complex is crucial for the G1 to S phase cell cycle transition.
- Dysregulation of this complex drives aggressive cancer cell proliferation.
- CDK4/6 inhibitors target this axis to arrest the cell cycle.
Purpose of the Study:
- To review the role of CDK4/6 inhibitors in breast cancer treatment.
- To highlight approved CDK4/6 inhibitors and their efficacy.
- To discuss the emerging therapeutic potential in triple-negative breast cancer.
Main Methods:
- Literature review of preclinical experiments and clinical trials.
- Analysis of the mechanism of action of CDK4/6 inhibitors.
- Examination of FDA-approved CDK4/6 inhibitors for breast cancer.
Main Results:
- CDK4/6 inhibitors effectively arrest the cell cycle at the G1 phase.
- Palbociclib, abemaciclib, and ribociclib are FDA-approved for advanced HR+ breast cancer.
- Emerging data suggests therapeutic effects in triple-negative breast cancer.
Conclusions:
- CDK4/6 inhibitors are a significant advancement in treating HR+ breast cancer.
- Targeting the cyclinD-CDK4/6-Rb axis offers a viable strategy against aggressive cancers.
- Further investigation into CDK4/6 inhibitors for triple-negative breast cancer is warranted.
Related Concept Videos
02:34Inhibition of Cdk Activity
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:39Positive Regulator Molecules